Daniel P. Petrylak, MD
The explosion of new checkpoint immunotherapy drugs has changed the paradigm of care for patients with urothelial carcinoma, the most common form of bladder cancer, according to experts who participated in a recent OncLive®
panel. Although chemotherapy regimens may still be the best first-line approach for some patients, other patients may benefit more from a checkpoint inhibitor.
moderator Daniel P. Petrylak, MD, and other experts in the field of genitourinary oncology discussed how immunotherapy is changing outcomes for patients with advanced bladder cancer.
Heterogeneity of Bladder Cancer
“Bladder cancer is a very heterogeneous disease, even within the metastatic state,” Petrylak said. Bladder cancers are broadly described as papillary or nonpapillary.2
Dean F. Bajorin, MD, explained that they are further subdivided into 3 main categories: metastatic bladder cancer, muscle-invasive bladder cancer (MIBC) without metastasis, and nonmuscle-invasive bladder cancer (ie, carcinoma in situ). The 3 types occur with different frequencies and require different management approaches.
... to read the full story